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Technetium-99m and rhenium-188 complexes with 
one and two pendant bisphosphonate groups for 
imaging arterial calcification 
Jayanta Kumar Bordoloi a, b, David Berry a, Irfan Ullah Khana,c, Kavitha Sunasseea, 
Rafael T.M. de Rosales a, Catherine Shanahanb, Philip J. Blower a. 
Abstract: The first 99mTc and 188Re complexes containing two pendant bisphosphonate groups have 
been synthesised, based on the mononuclear M(V) nitride core with two dithiocarbamate ligands each 
with a pendant bisphosphonate. The structural identity of the 99Tc and stable rhenium analogues as 
uncharged, mononuclear nitridobis(dithiocarbamate) complexes was determined by electrospray mass 
spectrometry. The 99mTc complex showed greater affinity for synthetic and biological hydroxyapatite, and 
greater stability in biological media, than the well-known but poorly-characterised and inhomogeneous 
bone imaging agent 99mTc-MDP. It gave excellent SPECT images of both bone calcification (mice and 
rats) and vascular calcification (rat model), but the improved stability and the availability of two pendant 
bisphosphonate groups conferred no dramatic advantage in imaging over the conventional 99mTc-MDP 
agent in which the bisphosphonate group is bound directly to Tc. The 188Re complex also showed 
preferential uptake in bone. These tracers and the biological model of vascular calcification offer the 
opportunity to study the biological interpretation and clinical potential of radionuclide imaging of vascular 
calcification and to deliver radionuclide therapy to bone metastases.  
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Introduction 
Techetium-99m (99mTc ) complexes of MDP (methylene diphosphonate, 1, figure 1) and related 1,1-bisphosphonates such as HDP 
(hydroxymethylene diphosphonate) have been used successfully for decades in the clinic for acquiring planar and SPECT images 
of osteoblastic processes associated with bone tumours and metastases.1-3 Another 1,1-bisphosphonate analogue, HEDP (2) has 
found use in palliative treatment of bone metastases with the beta-emitting rhenium isotopes rhenium-186 (186Re) and rhenium-188 
(188Re).4-7  Despite the proven value of these complexes in imaging and therapy, both the technetium and rhenium complexes have 
limitations. The structures of the active metal complexes are unknown, and certainly not homogenous.8 Despite their periodic 
relationship, the technetium and rhenium complexes are not chemically analogous (for example, the technetium complexes are 
biologically effective at no-carrier-added concentrations whereas the rhenium complexes are ineffective without carrier non-
radioactive rhenium,9 suggesting that they are polymeric). The complexes show poor in vivo stability; while this is not a major 
problem over the short time scales of imaging with 99mTc (typically 3 h) it is detrimental to therapeutic use of 186/188Re, as a high 
proportion of the rhenium is rapidly converted to perrhenate10, which does not bind to bone and is taken up in thyroid or excreted 
renally. The instability arises because the bisphosphonate groups in these ligands serve the dual purpose of binding the metal ion 
(for which they are not well-suited) and for bone targeting (in which their affinity may be compromised by the bound radiometal).   
 
In addition to the need for improved in vivo stability and therapeutic efficacy of bone-targeting rhenium complexes, new 
applications are emerging for imaging calcification (or decalcification) processes that place more stringent demands on imaging 
agents than conventional imaging of osteoblastic bone metastases. For example, imaging osteolytic lesions characteristic of 
multiple myeloma has very poor sensitivity with conventional 99mTc-bisphosphonate complexes,11 and imaging soft tissue 
calcification associated with cardiovascular diseases such as atherosclerosis and arterial calcification may require complexes with 
improved imaging characteristics because the lesions are small and mineral content and mineralisation/demineralisation rates may 
be low.  
 
Figure	  1:	  	  Bone	  targeting	  bisphosphonate	  derivatives	  for	  use	  with	  99mTc	  and	  188Re.	  
Dalton	  Discussions	   PREPRINT	  
This	  journal	  is	  ©	  The	  Royal	  Society	  of	  Chemistry	  2014	   Dalton	  Discussion	  XX	  |	  3 	  
 
 
To achieve the required improvements in in vivo stability and affinity for mineral deposits, we adopted the strategy of separating 
the metal chelating site from the bisphosphonate (bone targeting) site in a bifunctional molecule. This allows separate 
control/optimisation of metal chelation and bone targeting, exemplified by the ligand DPA-Alendronate (3) and its 99mTc12 and 
188Re13 complexes (4) using the readily-synthesised tricarbonyl [M(CO)3]+ cores. [188Re]-5 showed higher bone uptake and more 
prolonged bone retention of 188Re in vivo and higher biological stability compared with 188Re-HEDP (188Re-2) over a 24 hour 
period.13  The results indicate that [188Re]-5 has potential as an improved palliative agent for bone metastases, but remains non-
ideal due to modest uptake in non-target organs such as the liver, attributed to the increased lipophilicity of the complex.  
 
In this paper we extend the concept of bifunctional ligands for bone targeting, by synthesising complexes with increased mineral 
affinity by the inclusion of two pendant bisphosphonate groups in the molecule, and evaluating them in the challenging setting of 
an animal model of arterial calcification. The pentavalent technetium/rhenium nitrido bis(dithiocarbamate) core was identified as 
potentially meeting the requirements of retaining a structurally discrete, well-characterised and stable Tc/Re core with the 
expectation that the Tc and Re complexes will share similar biological behaviour. Precursors containing the [M≡N]2+ core (M = 
99mTc or 188Re) are readily synthesised14 and react with dithiocarbamates to give symmetrical MN(DTC)2 complexes.15-17  Despite 
the simplicity of the structures and syntheses, MN(DTC)2 complexes have found only limited use in radiopharmaceuticals, 
amongst which 99mTc-NOET for myocardial perfusion imaging has been most prominent.17, 18 Here we have used the ligand DTC-
BP (6), previously used to form a copper-64 complex,19 in a kit-based approach to synthesise the novel bis(bisphosphonate) 
complex 99mTcN(DTC-BP)2 ([99mTc]-7) and its rhenium analogues 8 and [188Re]-8, and compared their biological behaviour with 
that of the mono(bisphosphonate) derivative [99mTc]-4 and the conventional bone-imaging agent 99mTc-1. 
Experimental	  
Equipment and consumables   
TLC analyses were carried out using silica gel on aluminium-backed TLC plates (Merck 1.16834.0001) cut to 100 mm x 25 mm, 
using four mobile phase systems. Solvent system 1: ethanol/chloroform/toluene/0.5 M ammonium acetate (6/3/3/1);16  solvent 
system 2: methanol + 1% of a 60% solution of HEDP (Sigma H6773); solvent system 3: methanol/10% Ammonium Acetate (1/1) 
containing 15mM EDTA; solvent system 4: 1% HCl in methanol. The spots were allowed to dry before development in the mobile 
phase. Paper chromatography was carried out using Whatman 3MM paper or Whatman P81 paper and 0.9% saline as mobile 
phase. Radio-TLC chromatograms were analysed with a Mini-Scan TLC scanner (Bioscan) with FC3600 detector and γ-detector 
probe and Laura 4.0.2.75 (Lablogic) software. HPLC analyses were carried out on an Agilent 1200 series HPLC with degasser 
(G1322A), quaternary pump (G1311A), UV detector (G1314B) and manual injector (Rheodyne 7725i). The column used was an 
Agilent Zorbax Eclipse analytical XDB-C18 column (150 mm x 4.6 mm, 5 µm) unless otherwise indicated. Gamma counting of 
99mTc and 188Re samples was done using a 1282 Compugamma Gamma Counter (LKB Wallac) with Ultroterm software, counting 
for 10 seconds using a 110-155 KeV window. Higher activities were measured with a CRC-25R (Capintec) dose calibrator. Freeze 
!
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drying of samples was done using an Edwards freeze dryer connected to an Edwards RV8 vacuum pump. Mass spectra were 
acquired on an Agilent 6520 Accurate-Mass Q-TOF LC/MS with electrospray ionisation coupled to an Agilent 1200 HPLC system 
with degasser, quaternary pump and autosampler (G1329A), using Agilent Masshunter workstation acquisition software, B.02.1 
(B2116). Data were analysed using Agilent Masshunter Qualitative software B.03.01 (Build 3.1.346.14 service pack 3).  Sample 
shaking and centrifugation were done on a Grant PHMT shaker and an Eppendorf centrifuge 5424 microcentrifuge, respectively. 
99mTc-1 (99mTc-MDP, prepared by reconstitution of a Draximage kit with [99mTc]-pertechnetate eluted from a generator with 
physiological saline), was supplied by Guy’s Hospital Radiopharmacy, Guy’s and St Thomas’ NHS trust. [188Re]-perrhenate was 
eluted with physiological saline from a generator purchased from ITG (Isotope Technologies, Garching GmbH) and, where 
necessary, concentrated using a previously described procedure.20, 21 S-methyl-N-methyl-dithiocarbazate (DTCZ) was synthesised 
as previously described.22 
Radiolabelling and quality control of [99mTc]-4 
[99mTc-4] was synthesised and characterised according to procedures described previously.12,23 50 µg of DPA-ale in 300 µL of 50 
mM carbonate buffer (pH 9) containing 0.15 M NaCl was mixed with 300 µL of an aqueous solution of [99mTc]-[Tc(CO)3(H2O)3]+ 
(250-300 MBq) in a glass vial with a rubber stopper and heated at 90 oC for 30 min. The product was purified by passing it 
through a Sep-Pak C-18 Plus Light cartridge (Waters, WAT-23501) activated with absolute ethanol. [99mTc]-4 trapped by the 
column was eluted with 500 µL of 1:1 ethanol:water. The ethanol was then evaporated under a stream of nitrogen and the 
remaining solution diluted with 250 µL of saline for injection. The intermediates and product were analysed by radio-TLC using 
solvent system 4 on silica plates (intermediates: reduced hydrolysed technetium, Rf = 0; [Tc(CO)3(H2O)3]+, Rf = 0.1-0.7; 
pertechnetate, Rf = 0.9; product, [99mTc-4], Rf = 0). Radiochemical purity of the final product was >99%. 
 
Synthesis and mass spectrometry of [TcN(DTC-BP)2] (7)	  
K[99TcO4] (Amersham International plc, UK; 0.6 mg, 20 µL of a 30 mg/mL solution) was added to a vial containing 3.6 mg 
succinic dihydrazide (SDH) and 1.3 mg 1,2-diaminopropanetetraacetic acid (DPTA) in 500 µL physiological saline, followed by 
500 µL of a 10 mg/mL solution of SnCl2 in 0.05 N HCl.  The solution immediately turned yellow/orange and a precipitate formed.  
After 35 minutes the solution was centrifuged and 50 µL of the supernatant was added to 1.3 mg HDTC-BP (6), synthesised as 
described previously,19 in 400 µL of pH 10 carbonate buffer.  The solution was heated at 60oC for 30 minutes before cooling to 
room temperature and analysing by mass spectrometry using the LC-MS system without a column. The mobile phase was 15 mM 
ammonium bicarbonate, adjusted to pH 9.4 with 30% NH4OH solution.  The flow rate was 0.5 mL/min and a splitter was fitted 
(10% LC flow to mass spectrometer, 90% flow to waste). The mass spectrometer was run in negative ion mode with a gas 
temperature of 325oC, an N2 gas flow of 5 L/min and a nebuliser pressure of 20 psi. The capillary voltage was 3500 V and the 
fragmentor voltages were 175 V and 250 V. The injection volume for each sample was between 0.1 and 1 µL.   
Synthesis and mass spectrometry of [ReN(DTC-BP)2] (8). 
[ReNCl2(PPh3)2]24 was reacted with 1,3,5-triaza-7-phosphaadamantane (PTA) to produce the water-soluble complex 
[ReNCl2(PTA)3] according to an established method.25 This complex (8.9 mg, 1.12 x 10-5 mol) was dissolved in 1 mL water to 
give a cloudy brown solution which was then added to 6 (8 mg, 2.46 x 10-5 mol, 2.2 eq) and shaken at 800 rpm at room 
temperature for 80 min.  The solution was then freeze dried.  The freeze dried material was reconstituted to 1 mg/mL in water for 
mass spectrometry analysis, giving a clear yellow solution. This was analysed by mass spectrometry as described above for [99Tc]-
7 but with fragmentor voltage set at 125 V or 325 V. 
 
Radiolabelling of [99mTc]-7 
Method 1 (arrived at after extensive optimisation to ensure reliable quantitative radiochemical yield): To a vial containing SDH 
(2.5 mg) and DPTA (1 mg) in 500 µL saline was added 695 MBq 99mTcO4- generator eluate (120 µL), followed by 50 µL of a 10 
mg/mL solution of SnCl2 in 0.05 N HCl.  The mixture was shaken at room temperature for 1 h.  Quality control was performed 
using TLC with solvent system 1 (pertechnetate, Rf = 0.5; reduced hydrolysed technetium, Rf = 0; required technetium nitride 
intermediate, Rf = 0 – 0.3) and solvent system 2 (reduced hydrolysed technetium, Rf = 0; required technetium nitride intermediate 
and pertechnetate, Rf = 0.9). 300 µL of this solution was then added to a vial containing 0.5 mg 6 in 200 µL carbonate buffer, to 
give a total of 280 MBq in 500 µL.  The solution was heated at 60oC for 30 minutes, followed by quality control by TLC using 
solvent system 2 ([99mTc]-7, Rf = 0). For in vivo administration 200 µL of the solution was added to 80 µL 0.1 N HCl, to give 101 
MBq of 99mTc-7 in 280 µL with a final pH of 6.6-7. 
 
Method 2 (developed after optimising the synthesis via method 1): 623 MBq 99mTcO4- generator eluate (in 1 mL saline) was added 
to a lyophilised SDH kit vial (generous gift of Prof. Roberto Pasqualini, Cis Biointernational, IBA Group, Gif-sur-Yvette, France, 
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as previously used for production of 99mTc-NOET)17, 18 and incubated for 30 minutes at room temperature. The composition of the 
kit vial was as follows: SDH 5.0 mg; stannous dichloride dihydrate 0.10 mg; DPTA 5.0 mg; sodium dihydrogen phosphate 
monohydrate 0.6 mg; disodium phosphate heptahydrate 10.9 mg; under a dinitrogen atmosphere. Quality control was performed 
using TLC with solvent system 1. 300 µL of the resulting solution was then added to 300 µL of the of DTC-BP ligand (1 mg/mL) 
in carbonate buffer (pH 10). The vial was incubated at 60 ⁰C for 30 minutes. QC was performed using TLC with solvent system 2. 
Radiolabelling of [188Re]-8 
Kit vials were prepared as follows: 1.5 mg DTCZ was placed in a nitrogen-purged vial followed by 2.8 mg/mL SnCl2.2H2O 
dissolved in 0.5 mL of 20 % glacial acetic acid and 28 mg sodium oxalate. The vial was capped with a rubber stopper, sonicated 
and purged with nitrogen for 10 min. To a kit vial thus prepared, 500 MBq 188ReO4- in 0.5 mL generator eluate was added. The 
vial was vortex-mixed, heated at 80°C for 2-3 min and allowed to cool to room temperature for 15 min. TLC was performed using 
solvent system 1 above. This intermediate solution as also analysed by radioHPLC using an Agilent HPLC with an Eclipse XDB-
C18 column (4.6 x 150 mm) and a guard column eluted with 95% water, 5% methanol each with 0.1% trifluoracetic acid, at a flow 
rate of 1 mL/min. In this system perrhenate (5% of eluted activity) eluted at < 2 min, while the rhenium nitride intermediates (95% 
of eluted activity) eluted as a series of isomeric species at 10-13 min. 50 µL of this solution of 188Re-nitride intermediate was then 
added to 71.4 µg DTC-BP in 100 µL carbonate buffer (0.5 M, pH 9.0), to give a total of 25 MBq in 150 µL. The solution was 
gently vortexed and heated at 80°C for 30 min, followed by quality control by TLC using solvent system 3 (perrhenate, Rf = 0.8-
0.9; [188Re]-8, Rf = 0). 
LogP measurement 
The lipophilicity of each 99mTc and 188Re radiotracer, with a radiochemical purity of at least 95%, was determined by partitioning 
the complex between 1-octanol and water. 50 µl (~1-2 MBq) of the radiotracer was added to a 1.5 mL Eppendorf tube (n = 9) 
containing 500 µL 1-octanol and 495 µL of distilled water and vortexed at room temperature for 15 minutes and then centrifuged 
at 1200 RPM for 5 minutes. A 0.2 mL aliquot of each phase was pipetted out and counted in a gamma-counter. The partition 
coefficient was calculated as logP = log((cpm in octanol–cpm background)/(cpm in water–cpm background)). 
 
Synthetic and biological mineral binding studies 
Preparation of mineral salts and buffer solutions: 1 mg of each bone mineral analogue (hydroxyapatite, β-tricalcium phosphate, 
calcium phosphate dibasic, calcium oxalate, calcium carbonate or calcium pyrophosphate, all purchased from Sigma-Aldrich) was 
added to a 1.5 mL plastic microcentrifuge tube in duplicate. 1 mL TRIS-HCl buffer (50 mM, pH 6.8) was added to each tube 
followed by 10 µL of either 99mTc-7 (prepared by method 1) or 10 µL of the 99mTcN2+ intermediate (method 1, as a control).  10 µL 
of either tracer were also added to control tubes containing 1 mL TRIS-HCl with no mineral salts. All tubes were then shaken at 
900 rpm for 1 h then centrifuged at 10,000 rpm for 5 min. 10 µL of supernatant was removed from each tube (including the 
controls) and added to 1 mL TRIS-HCl buffer (50 mM, pH 6.8) in triplicate. Percentage binding of radioactivity to the mineral 
salts was calculated as (1 - cpmsample/cpmcontrol) x 100%. 
 
Similar studies were performed with mineral samples of biological origin, including powdered equine bone and human minerals 
isolated from vascular intimal and medial calcified plaques obtained from surgical procedure with appropriate ethical approval. 
The methods to release these biominerals from their organic matrix and connective tissues have been previously published.26, 27 
Suspensions of 0.5 mg/mL of each sample were prepared in distilled water. 1 mL of the suspensions in triplicate (synthetic 
hydroxyapatite, powdered equine bone, medial and intimal arterial minerals) was placed in 1.5 mL Eppendorf tubes in triplicate 
alongside mineral-free controls. 20 µL of 99mTc-1, [99mTc]-4 and [99mTc]-7 (0.5-1 MBq) was added to each tube. The tubes were 
incubated for 60 min in a shaker at 37 ⁰C and 550 RPM. The tubes were centrifuged at 13,200 RPM for 5 minutes. 50 µL of the 
supernatant from the vials were pipetted out and counts were measured in a gamma counter. The binding percentage was 
calculated as above.  
 
Hydroxyapatite binding in the presence of serum and serum protein binding   
To microcentrifuge tubes containing 2 mg/mL hydroxyapatite in TRIS-HCl buffer (50 mM, pH 6.8) or human serum (Sigma) were 
added 10 µL of either [99mTc]-7 or 99mTc-1. Identical controls without mineral were prepared similarly. All tubes were prepared in 
triplicate. All samples were then incubated with shaking at 1400 rpm at 37oC. At intervals of up to 23 h all tubes were centrifuged 
at 10,000 rpm for 5 minutes. 5 µL supernatant was removed from each tube and counted in a gamma counter.  Hydroxyapatite % 
binding was calculated as described above. Binding to serum proteins in the serum-containing samples was assessed as follows: 70 
µL ethanol was added to 50 µL aliquots of the supernatant after centrifugation of each serum incubation. The tubes were 
centrifuged at 10,000 rpm for 5 minutes and the supernatant was removed. The pellets were washed with another 70 µL ethanol, 
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centrifuged again and the supernatant was decanted and added to the supernatant from the initial precipitation. The pellets and 
supernatant were then counted separately in a gamma counter. Percentage serum protein binding was calculated as 100% x 
cpmpellet/(cpmpellet+cpmsupernatant). Control samples of [99mTc]-7 in buffer were also subjected to ethanol precipitation to ascertain 
whether or not the addition of ethanol caused the complex to precipitate. 
Animal studies 
All procedures were performed in accordance with licences and guidelines approved by the UK Home Office and were approved 
by a King’s College ethics committee. Normal female BALB mice, 9 weeks old, were used for preliminary comparative 
biodistribution studies with 99mTc-1, [99mTc]-7 and [188Re]-8. For imaging of arterial calcification, Sprague Dawley rats (n = 6; 
male; 21-27 days old) were purchased from Charles River Laboratories. After an acclimatisation period of 7 days, 6 rats were fed 
with a diet containing warfarin (3 mg/g food) and vitamin K1 (1.5 mg/g food) for 11 days. The rats were given 200,000 IU/kg/day 
subcutaneous injections of cholecalciferol (Sigma- 47763) from day 7 to day 11 of the diet.  It has been reported that warfarin 
treatment in the form of diet, oral administration (gavage) or subcutaneous injections induces vascular calcification27, 28 and the 
process is accelerated by vitamin D3 (cholecalciferol). All animals were maintained on a 12 hour light-dark cycling with access to 
environmental enrichment (tunnel). Food and water were provided ad libitum. 
 
SPECT/CT scanning and biodistribution: Mice (n=1) under Isoflurane anaesthesia were injected with 40 MBq of either [99mTc]-1 
or [99mTc]-7 in ~ 100 µL via a tail vein. SPECT-CT scans were acquired at intervals up to 338 min using a NanoSPECT-CT 
scanner (Bioscan, USA) with SPECT acquisition time 1800 s, obtained in 24 projections using a 4-head scanner with 4 × 9 (2 mm) 
pinhole collimators in helical scanning mode and CT images with a 45 kVP X-ray source, 500 ms exposure time in 180⁰ 
projections over 9 min. Images were reconstructed in a 128 × 128 matrix using HiSPECT (ScivisGmbH), a reconstruction software 
package, and images were fused using proprietary Bioscan InVivoScope (IVS) software. All scans were 30 minutes long. Kinetic 
studies (% uptake) were carried out by calculating the radioactivity in local regions of interest (ROIs) relative to the radioactivity 
in the whole body ROI.  ROI data were calculated for both a knee joint and a single vertebra. The mice were sacrificed with an 
overdose of anaesthesia at the end of scanning and the organs and tissues were harvested, weighed and counted in a gamma 
counter. Uptake was reported as standard uptake values (SUVs). Rats under Isoflurane anaesthesia were injected with 40-50 MBq 
(100 µL) of the radiotracers via a tail vein with 99mTc-1, [99mTc]-4 or [99mTc]-7 (n = 2 in each case). CT images were acquired with 
a 55 kVP X-ray source, 100 ms exposure time in 360⁰ projections over 24 min. SPECT imaging was performed with above 
mentioned parameters at intervals of 30 min up to 240 min. After 4 hours of SPECT-CT scanning the rats were culled by an 
overdose of anaesthesia. Vital organs were harvested, weighed and counted with a gamma counter, along with standards prepared 
from a sample of the injected material. The percent of injected dose per gram of tissue (% ID/g) was calculated. Biodistribution of 
[188Re]-8 was determined similarly (n = 3) after injection of 8.5 MBq (50 µL) of the radiopharmaceutical. Mice were killed at 24 h 
post-injection and organs harvested as described above, weighed and counted in a gamma counter. 
 
Figure	  2:	   	   Intermediates	  and	  products	  (the	  latter	  as	  identified	  by	  detection	  of	  corresponding	  molecular	  ions	  in	  electrospray	  mass	  spectrometry)	   in	  the	  synthesis	  of	  
rhenium	  nitride	  complexes.	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Figure	   3:	   Radio-­‐TLC	   chromatograms	   on	   silica	   gel	   coated	   aluminium	   plates	   of	   (A)	   99mTcO4
-­‐,	   solvent	   system	   1;	   (B)	   99mTcN2+	   intermediate,	   solvent	   system	   1,	  
(demonstrating	  the	  absence	  of	  pertechnetate	  at	  this	  stage);	  (C)	  99mTcN2+	  intermediate,	  solvent	  system	  2	  and	  (D)	  99mTc-­‐7,	  solvent	  system	  2	  (demonstrating	  the	  absence	  
of	  both	  pertechnetate	  and	  the	  Tc-­‐nitride	  intermediate	  in	  the	  final	  product).	  
 
 
 
Results	  
Chemical syntheses and characterisation 
[TcN(DTC-BP)2] (7): The beta-emitting isotope 99Tc has a long half-life (200,000 years) and hence, unlike the gamma-emitter 
99mTc, a low enough specific activity to be handled in quantities sufficient to perform conventional spectrometry. Compound 8 was 
synthesised by a scaled-up version of the no-carrier-added method used with 99mTc (see below), starting from potassium 
pertechnetate and reducing it with stannous chloride in the presence of succinic dihydrazide as a nitride source and propane-1,2-
diamine tetraacetic acid as an intermediate chelator of the technetium complex and possibly of tin. Like the rhenium analogue (see 
below for details), the clear yellow solution resisted isolation of the product in pure form by virtue of its intractable solubility and  
chromatography properties, and was therefore characterised by electrospray mass spectrometry (again, like the rhenium analogue 
discussed below). Negative ion mass spectra of the yellow 99Tc solution show that at 250 V the only technetium-containing ions 
detected were those derived from the expected molecule 7 i.e. (M-H)- (m/z = 759.8003) and sodium adducts (M-2H+Na)- 
(781.7815) and (M-3H+2Na)- (803.7624).  At 175 V the doubly charged (M-2H)2- species was also present.  No ions containing Tc 
in a form other than this (e.g. with oxo-ligand rather than nitride, or with a ligand-to-metal ratio other than 2:1, or oligomeric 
species) were detected. A full list of ions can be found in table S2 of the supplementary data, along with raw spectra. 
[ReN(DTC-BP)2] (8): Synthesis of 8 was achieved in three steps.  The well-known Re(V) nitride precursor [ReNCl2(PPh3)2] was 
synthesised according to an established method24 and was then reacted with 1,3,5-triaza-7-phosphaadamantane (PTA) to make the 
water-soluble [ReNCl2(PTA)3] according to an established method.25 The aqueous solubility of [ReNCl2(PTA)3] enabled its 
reaction with the dithiocarbamate-bisphosphonate conjugate 5 which is soluble only in water; the resulting clear yellow aqueous 
solution was typical in appearance to previously reported [ReN(dtc)2] complexes but because of the extreme water solubility of the 
product, its extreme insolubility in non-aqueous solvents, and its strong adherence to all of the wide variety of chromatographic 
stationary phases tested (including reverse-phase silica-based HPLC media) it remained resistant to isolation in pure form. 
Therefore the crude clear yellow aqueous solution was analysed by electrospray mass spectroscopy (in negative mode due to the 
expected negative charge), as the only analytical approach by which the complex could be characterised without interference from 
other components of the mixture. Because of the irreversible adsorption to all chromatographic media, the LC-MS system was 
used without a column. The sample was analysed at two different cone voltages. At 325 V the only ion species showing the characteristic 
185/187Re isotope pattern were the negatively charged ions corresponding to the expected molecule 8 ionising by loss of H+ or 2H+, and 
variants with H+ replaced by Na+. In the case of the dominant 187Re isotope these were (M-H)- complex (m/z = 847.8721) and related sodium 
0
50
100
150
200
250
300
350
400
-­‐0.1 0.1 0.3 0.5 0.7 0.9 1.1
Co
un
ts
Rf	  value	  
0
100
200
300
400
500
600
700
800
-­‐0.1 0.1 0.3 0.5 0.7 0.9 1.1
Co
un
ts
Rf	  value	  
0
50
100
150
200
250
300
350
-­‐0.2 0 0.2 0.4 0.6 0.8 1
Co
un
ts
Rf	  value	  
(B) 
(C) (D) 
0
100
200
300
400
500
600
700
800
900
-­‐0.1 0.1 0.3 0.5 0.7 0.9 1.1
Co
un
ts
Rf	  value	  
(A) 
Dalton	  Discussions	   PREPRINT	  
This	  journal	  is	  ©	  The	  Royal	  Society	  of	  Chemistry	  2014	   Dalton	  Discussion	  XX	  |	  8 	  
adducts (M-2H+Na)-  (869.8517) and (M-3H+2Na)- (891.8341), and doubly charged relatives (M-2H)2- (m/z = 423.4129) and related sodium 
adducts (M-3H+Na)2- (434.4033) and (M-4H+2Na)2- (445.3949). The mass spectrum also showed another 187Re species with m/z 765.8919 
(together with its 185Re partner), corresponding to a fragmentation involving loss of P(OH)3 and ionisation by loss of H+. No ions of higher 
molecular weight that would indicate oligomeric species, or with ratios of ligand-to-rhenium nitride other than 2:1, or indeed rhenium species 
not containing the nitride ligand, were detected in the mass spectrum at 325 V. At 125 V, the main species identified were again the doubly 
charged (M-2H)2- derived from 8  and related sodium adducts (M-3H+Na)2- and (M-4H+2Na)2-. However, also present at 125 V were peaks 
derived from [ReN(DTC-BP)2(PTA)] with (M-H)- and (M-2H)2- and related sodium adducts.  There was also a set of peaks relating to 
ReN(DTC-BP)3 (M-H). The absence of these peaks from the 325 V spectrum of the same sample suggests that they appear of greater 
significance under the milder ionisation conditions because the major species derived from 8 itself are less efficiently ionised at this low 
voltage. A full list of ions can be found in table S1 of the supplementary data along with the raw spectra.  
Radiolabelling and quality control of [99mTc]-7 
The radiolabelling method was developed from the established two-step methods used for radiolabelling the lipophilic 
99mTcN(DTC)2 complexes such as 99mTc-NOET.15-17 The general method was to make the pentavalent 99mTcN2+ intermediate 
(presumably with PDTA as ancillary ligands) from pertechnetate by stannous reduction in the presence of succinic dihydrazide as 
the nitride source in the first step before adding this solution to the dithiocarbamate (in this case 5) in the second step.  As expected 
from the adsorption and solubility behaviour of 8 (above), analysis of radiochemical purity of [99mTc]-7 using reverse phase HPLC 
proved to be unsuccessful, leading to retention of all radioactivity on all columns evaluated (whether reverse- or normal-phase) 
even after prolonged washing with various solvents. The nitride intermediate and the starting pertechnetate were, on the other 
hand, eluted successfully from HPLC columns and migrated in suitable TLC conditions, as expected. Two solvent systems were 
adopted for quality control using silica gel TLC. Solvent system 1 could distinguish between 99mTcO4- and the 99mTcN2+ 
intermediate (Figure 3, A and B respectively).  Solvent system 2 could distinguish between the 99mTcN2+ intermediate and [99mTc-
7] (Figure 3, C and D respectively); all three species could be distinguished using these two systems. Thus, the main evidence for 
the formation of the required [99mTc]-7 is the presence of a radioactive species with Rf = 0 under conditions of both TLC methods 
1 and 2; no such species appeared at earlier stages of the synthesis. These TLC methods were used to optimise the kit-based 
process for synthesising [99mTc]-7, before finally arriving at the conditions described in the experimental section. Octanol-water 
solvent extraction confirm that [99mTc]-7 is highly hydrophilic (logP = -2.76 ± 0.08), and its increased lipophilicity compared to 
99mTc-1 and [99mTc]-4 (logP = -2.40 ± 0.16 and 2.05 ± 0.03 respectively; see supplemental information) is consistent with the 
presence of two pendant bisphosphonate groups. 
Radiolabelling and quality control of [188Re]-8 
The approach to 188Re radiolabelling was similar to that used for 99mTc labelling. First a labelled rhenium-nitrido intermediate was 
prepared using stannous chloride to reduce rhenium from Re(VII) to Re(V) and DTCZ as a source of the nitride group, as 
previously described.29 TLC and HPLC showed that at this stage 95% of perrhenate had been converted to the intermediate. This 
intermediate was then treated with the dithiocarbamate ligand to produce [188Re]-8, which was used both to confirm the 
equivalence of the radioactive species by TLC with the cold complex characterised by mass spectrometry, and for preliminary 
biodistribution studies. The final TLC showed that no perrhenate or intermediate remained in the product. As in the case of 
[99mTc]-7, no HPLC or TLC conditions could be found in which the product could be eluted from the stationary phase. 
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Figure	  4	  Graph	  showing	  results	  of	  bone	  mineral	  binding	  studies	  of	  [99mTc]-­‐7	  (hatched	  bars)	  and	  99mTcN2+	  intermediate	  (black	  bars).	  
	  
In vitro bone mineral binding studies 
To determine the propensity of the complexes to bind to hydroxyapatite (HA) and other calcium phosphates, as a crude in vitro 
assessment of bone targeting potential and to confirm the availability of bisphosphonate groups for mineral binding, [99mTc]-7 was 
mixed with a suspension of hydroxyapatite and allowed to partition between solid and solution phase. Binding of [99mTc]-7 was 
high for each mineral salt with values ranging between 59% for β-tricalcium phosphate up to 90% for hydroxyapatite as shown in 
figure 4. “Non-specific” binding of radioactivity of the 99mTcN2+ intermediate to mineral salts was very low with all values ≤ 1.6%. 
This encouraging result prompted comparison of [99mTc]-7 with the other 99mTc-bisphosphonate complexes, 99mTc-1 and [99mTc]-4, 
in their affinity for synthetic and biologically-derived calcium phosphates. 
Each of these 99mTc-complexes was incubated with 0.5 mg/mL of synthetic HA, equine bone and isolated minerals from human 
intimal and medial atherosclerotic plaque samples. The results are shown in figure 5. The percentages of 99mTc-1, [99mTc]-4 and 
[99mTc]-7 bound to synthetic HA were 88.5±0.9%, 92.4±0.7% and 94.5±3.05% respectively. A similar range and ranking was 
observed with powdered bone and with mineral from medial calcified plaques. However with the minerals isolated from intimal 
plaques the % binding was significantly lower (possibly because these minerals contain a lipid component) and the MDP complex 
had a markedly reduced tendency to bind compared to the pendant bisphosphonate complexes. 
 
Figure	   5:	   	   Graph	   showing	   the	  %	  binding	   (mean	   ±SD)	   of	   99mTc-­‐1,	   [99mTc]-­‐4	   and	   [99mTc]-­‐7	  with	   synthetic	   hydroxyapatite,	   powdered	   equine	  bone	   and	  minerals	   from	  
intimal	  and	  medial	  plaques.	  *significant	  a	  p>0.05,	  **significant	  at	  p>0.001	  and	  ***significant	  at	  p>0.0001.	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Binding to hydroxyapatite and proteins in serum 
99mTc-1 and [99mTc]-7 were incubated in serum (and a non-phosphate buffer, as a control) with and without hydroxyapatite over a 
period of 23 h in order to determine whether a biological milieu interferes with mineral binding, and to compare their binding to 
serum proteins. [99mTc]-7 binds well (>90%) to hydroxyapatite in buffer and only slightly less well (>80%) in serum, and the 
binding is largely retained during the 23 h. 99mTc-1 on the other hand binds less well in buffer (>60%) in qualitative agreement 
with figure 6 despite the changed conditions, and the binding is severely diminished (>30%) by the presence of serum; moreover 
the fraction bound in buffer diminishes with time (to ca. 35% by 23 h), whereas there is no corresponding loss of binding with 
time in serum. Possibly this behaviour is associated with vulnerability of 99mTc-1 to gradual oxidation to pertechnetate, against 
which serum may offer some protection, and to which [99mTc]-7 is less sensitive because of the more appropriately designed 
chelator used. Both complexes display a high level of binding to proteins (70-80% in the case of [99mTc]-7, 60-70% in the case of 
99mTc-1), with a much faster loss of protein binding over time in the case of 99mTc-1, possibly again because of gradual oxidation 
to pertechnetate. 
 
Figure	  6:	  	  Graph	  showing	  binding	  of	  [99mTc]-­‐7	  to	  hydroxyapatite	  in	  buffer	  (black	  solid	  line)	  and	  in	  serum	  (black	  dotted	  line);	  99mTc-­‐MDP	  in	  buffer	  (grey	  solid	  line)	  and	  in	  
serum	  (grey	  dotted	  line).	  
 
 
Biodistribution and imaging 
The biodistribution of the new tracer [99mTc]-7 was compared with that of the conventional bone imaging agent 99mTc-1 in normal 
mice. Both tracers (figure 7) show qualitatively similar biodistribution, with high uptake in bone and especially the joints, no 
marked uptake in any other tissue except kidney and bladder but a marked difference in the rate at which the tracer accumulates 
and clears through the renal pathway. The biodistribution of 99mTc-1 reached a steady state by 100 min, with renal excretion 
essentially complete and no further uptake in or clearance from bone and joints. [99mTc]-7 on the other hand was still visibly being 
excreted through kidney at this time, while figure 8 shows that activity continued to migrate from blood and soft tissues to bone 
and joints until at least 6 h. Although the SUV of [99mTc]-7 in bones and joints was lower than that of 99mTc-1 at 1 h, by 2 h the 
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SUVs were similar and by 6 h the SUV of [99mTc]-7 was significantly higher than that of 99mTc-1. The bladder (removed from the 
image for clarity of display) contained 61% of the radioactivity from 104 minutes onwards for 99mTc-1 compared with 24% at 54 
minutes for [99mTc[-7, rising to 28% at 365 minutes post injection.  
Figure	  7:	  	  SPECT	  images	  (coronal	  sections)	  of	  a	  mouse	  injected	  with	  [99mTc]-­‐7	  at	  54	  min	  (A)	  and	  365	  min	  (B),	  and	  of	  a	  mouse	  injected	  with	  99mTc-­‐1	  after	  104	  min	  (C)	  and	  
368	  min	  (D),	  post	  injection.	  	  The	  bladders	  have	  been	  digitally	  removed	  from	  the	  field	  of	  view	  for	  the	  sake	  of	  clarity.	  All	  scans	  show	  high	  uptake	  in	  bone	  and	  especially	  
joints.	  A	  and	  B	  show	  transit	  and	  retention	  of	  activity	  by	  kidney,	  whereas	  in	  C	  and	  D	  the	  renal	  excretion	  process	  is	  essentially	  complete	  and	  the	  kidneys	  are	  not	  evident.	  
 
 
Biodistribution data at 6 h post injection are shown in Fig. 9. SUVs are higher in bone and joint for [99mTc]-7 compared with 
99mTc-1 but non-specific binding in most soft tissues is higher for [99mTc]-7 particularly in the kidneys because of slower excretion 
and slower binding to bone, and minor uptake in trachea, spleen and liver. Also of note from figure 8 is that [99mTc]-7 displays a 
higher ratio of uptake in joint to mature bone than 99mTc-1. 
 
Figure	  8:	  	  Graph	  showing	  uptake	  in	  knee	  joint	  (solid	  lines)	  and	  single	  vertebra	  (broken	  lines)	  over	  6	  h.	  	  99mTc-­‐7	  is	  represented	  by	  black	  lines,	  99mTc-­‐1	  is	  represented	  by	  
grey	  lines.	  
 
 
 
Figure	  9:	  	  Standard	  Uptake	  Values	  (SUVs)	  for	  99mTc-­‐1	  (grey	  bars)	  and	  [99mTc]-­‐7	  (black	  bars)	  in	  mice	  at	  6	  h	  post	  injection.	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The new rhenium-188 radiopharmaceutical [188Re]-8, like [99mTc]-7, shows high specificity for bone and joints in preliminary 
biodistribution studies in mice (see supplemental information). Radioactivity concentration in bone and joints is high at 24 h (a 
much later time point than in the evaluation of its 99mTc analogue) and higher than in kidney and other tissues.  
 
The ability of the tracers to detect vascular calcification was compared in a rat model in which arterial calcification was induced by 
administration of warfarin and vitamin K in the diet and vitamin D subcutaneously. The resulting arterial calcification in the aorta 
and mesenteric arteries was confirmed by histological staining (see supplemental information). SPECT-CT scans (figure 10 and 
supplemental information) were then performed with novel agents [99mTc]-7 and [99mTc]-4 and the conventional agent 99mTc-1. As 
well as in bones and joints, intense uptake of all the radiotracers was most strikingly seen in the calcified mesenteric artery within 
30 min of the injection. This manifests as a hollow sphere of activity, in the abdominal region below the liver that does not 
correspond to any major solid organs and is not visible in scans of normal rats. Ex-vivo biodistribution demonstrates significantly 
increased uptake (%ID/g) in most tissues (including bones) compared to normal rats; of the tissues that could be dissected and 
weighed (which do not include the mesenteric arteries), the increase is particularly marked for all three tracers in the aorta, heart 
and lungs (figure 11) although uptake in these organs is still too small to be clearly evident on the scans at the thresholds used in 
figure 10. While these data demonstrate the ability of the new tracers to detect vascular calcification, at the present stage of 
analysis they do not demonstrate any dramatic advantage in sensitivity of the new tracers with pendant bisphosphonate groups 
compared to the conventional heterogeneous tracer 99mTc-1 in this application.  
Discussion  
We have described a simple synthesis and radiolabelling of the first technetium and rhenium complexes with two pendant 
bisphosphonate groups, building on the early development of complexes in which bisphosphonate groups are bound directly to the 
radiometal (and which have become established radiopharmaceuticals for imaging and palliative therapy of bone disease2) and the 
later development of complexes containing a pendant bisphosphonate group.12, 13 We reasoned that this sequence of developments 
in design should yield radiopharmaceuticals with improved homogeneity, in vivo stability and targeting of biomineral deposits. To 
produce a well-defined complex with two pendant bisphosphonate groups we chose to use the well-known technetium/rhenium(V) 
nitridobisdithiocarbamate core, in conjunction with a dithiocarbamate-bisphosphonate conjugate ligand, 6, which we previously 
showed to coordinate to copper(II) via its dithiocarbamate group to form a complex with two pendant bisphosphonate groups.19 
 
Figure	  10:	  	  A,	  B:	  Coronal	  sections	  of	  a	  rat	  scanned	  30	  min	  and	  4	  h,	  respectively	  after	  i.v.	  injection	  of	  [99mTc]-­‐7.	  C,	  D:	  Coronal	  sections	  of	  a	  rat	  scanned	  at	  30	  min	  and	  4	  h,	  
respectively,	  after	   i.v.	   injection	  of	   [99mTc]-­‐4.	  E,	  F:	  Coronal	  sections	  of	  a	  rat	  scanned	  at	  30	  min	  and	  4	  h,	  respectively,	  after	   i.v.	   injection	  of	   99mTc-­‐1.	  Arrows	  show	  the	  
uptake	  of	  the	  radiotracers	  in	  the	  calcified	  mesenteric	  arteries.	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The synthesis of the 99Tc and 99mTc complexes is based on the established formation of a M(V) nitride complex using succinic 
dihydrazide as a source of nitrogen to form the nitride.17, 18 To establish a robust, kit-based synthesis with sufficiently high yield 
(>95%) to avoid the need for a purification step, it was necessary to optimise the composition of the kit and in particular to ensure 
that the concentrations and molar ratios of the intermediate chelator DPTA and the final ligand 6 were appropriately balanced: too 
little DPTA leads to inadequate stabilisation of the metal nitride intermediate, while too much causes competition with the 
dithiocarbamate ligand in the second step. This optimisation led to methods 1 and 2 each of which provides a simple route to the 
99mTc complex. The 99Tc analogue was also synthesised, using the same reagents, to generate sufficiently high concentrations for 
analysis by mass spectrometry. The route to the rhenium complex was based on conventional rhenium nitride starting materials, 
adapted for compatibility with an aqueous synthesis because 6 is only soluble in water. 
 
The characterisation of the product complexes posed major problems because the solubility and adsorption properties of both 7 
and 8 precluded purification by recrystallisation or chromatography. The bisphosphonate complexes are all extremely hydrophilic 
(see logP data, supplemental information) and adherent to various stationary phases. As a result, only negative ion electrospray 
mass spectrometric data are available to confirm the identity of the products. The mass spectra, however, confirm several key 
aspects relating to the structure and homogeneity of both 7 and 8. The ions observed are consistent with the presence of a 
mononuclear nitrido complex with two dithiocarbamate-bisphosphonate ligands, with the metal in oxidation state five. This is 
consistent with the body of literature on technetium and rhenium nitride bis(dithiocarbamate) complexes.14 These data cannot, 
however confirm that ligand is coordinated through the dithiocarbamate group rather than the bisphosphonate group; but 
comparison with literature on technetium and rhenium with coordinated bisphosphonates would suggest such complexes are 
inhomogenous and polymeric,8, 9 and there is no evidence of such behaviour in the mass spectra of 7 and 8. Moreover, 
dithiocarbamates are well known to form transition metal complexes with high affinity, whereas bisphosphonates and 
pyrophosphates are have been used because of their relative instability, as intermediate chelators to make metastable Tc 
intermediates in which the bisphosphonates are ultimately displaced by more powerful ligands (e.g. during protein radiolabelling 
at thiol groups of reduced antibodies30). The mass spectra are also unable to distinguish possible isomers due to the different 
relative orientations of the ligands (e.g. syn- and anti- disposition of the methyl groups of the two ligands); however, this is 
unlikely to be problematic because the metal coordination sphere in this class of complexes is well-known to be highly fluxional. 
The equivalence of carrier free (radiolabelled, characterised only by virtue of its Rf value of zero on TLC) and carrier added 
(185/187Re and 99Tc, identified by mass spectrometry and Rf value of zero on TLC) is demonstrated only by sharing Rf values of 
zero in various TLC conditions and failure to elute from various HPLC columns. This is weak evidence because many species 
such as reduced hydrolysed Tc share this property. However, although differences in structure and speciation of radioactivity are 
often observed in technetium complexes at the tracer an macroscopic levels, these typically involve oligomerisation at the higher 
concentration but not at the lower; since the high concentration solutions here have been shown by mass spectrometry to contain 
only mononuclear complexes, there is no reason to doubt that the tracer level complexes are also mononuclear.  
 
Figure	  11:	  	  Biodistribution	  	  (%ID/g,	  mean±SD)	  in	  rats	  4	  h	  after	  injection	  of	  tracers	  99mTc-­‐1,	  [99mTc]-­‐4	  and	  [99mTc]-­‐7	  (n=2).	  	  
A	   	   	  	  	  B	   	   	  	  	  	  	  	  C	  	   	  	  	  	  	  	  	  D	   	   E	   	   	  	  	  	  F	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Both the new pendant tracers [99mTc]-4 and [99mTc]-7 show improved binding both to synthetic calcium-based minerals and to 
hydroxyapatite-like minerals isolated from human calcified tissue, and improved stability in buffer and serum compared to 99mTc-
1, as indeed they were designed to do. This advantage is conferred by the design of the metal coordinating ligands to match the 
known preferences of the metal core, rather than relying on the relatively poor chelating ability of the bisphosphonate group. This 
translates into improved stability in buffer and blood serum, and in vivo, which in turn leads to higher uptake in bone and calcified 
soft tissues than 99mTc-1. However, this potential advantage is set against disadvantage of the greater time taken to achieve the best 
target-to-background ratio in vivo. Thus, the advantages in practical use are likely to arise in situations where prolonged action are 
important, that is, therapeutic applications of the longer lived isotopes 188Re (17 h) and 186Re (90 h) rather than imaging 
applications of the short lived 99mTc (6 h). These advantages will be manifested if the biodistribution and kinetics of the Tc and Re 
analogues prove to be the same, as they have done in the case of [99mTc]-4 and [188Re]-512, 13; preliminary in vivo biodistribution 
studies suggest that this is also the case for [188Re]-8 (see supplemental information). [188Re]-8 shows the expected and desired 
specificity for bone and joints and low retention in kidney, at 24 h, giving a qualitative indication of prolonged in vivo stability. 
Although quantitative comparison with other rhenium-188 bone targeting radiopharmaceuticals has not been part of this study, the 
data suggest that [188Re]-8 will have advantages over 188Re-HEDP and warrants further evaluation as a radiopharmaceutical for 
radionuclide therapy of bone metastases. Thus both [188Re]-5 and [188Re]-7 are likely to offer improvements in radionuclide 
therapy compared to the conventional agents 188/186Re-HEDP. 
  
31P NMR and X-ray powder diffraction studies of calcified plaques from animals and humans show that the minerals present in 
vascular calcification closely resemble hydroxyapatite.31 Radiolabelled bisphosphonates bind avidly with hydroxyapatite; hence 
they have the potential to be used as agents for imaging of vascular calcification. This prediction presupposes that the mechanism 
of uptake in calcified tissue and bone is through direct binding to mineral – but it could also be related to cellular transport 
mechanisms involving osteoclast/osteoblast-like cells involved in the calcification process, as has been implicated in the 
mechanism of action of bisphosphonate drugs used to treat bone disorders.32 Nevertheless it is consistent with the observation that 
the tracers described here bind to the pathological mineral samples tested, and the in vivo results show that the tracers indeed target 
not only bone but also vascular soft tissue calcification. There have been previous reports of extra-osseous uptake of 99mTc-1 
linked with atherosclerosis and vascular calcification. For example DeLong et al. reported the visualisation of calcified femoral 
arteries in delayed images of patients undergoing bone scans.33 The clinical value of imaging vascular calcification has, however, 
yet to be fully explored. 
Conclusion 
The new technetium and rhenium complexes with two pendant bisphosphonate groups have been synthesised by simple methods 
amenable to kit-based radiolabelling. The presence of one and two pendant bisphosphonate groups confers advantages over 
conventional bisphosphonate complexes in which the bisphosphonate group is involved in technetium or rhenium chelation, in 
terms of in vivo stability and affinity for hydroxyapatite of synthetic and biological origin. These advantages are likely to be 
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significant in therapeutic applications involving the longer half-life isotopes 186Re and 188Re. All three classes of 99mTc complex 
described here are capable of imaging vascular soft tissue calcification as well as bone disease. The tracers and biological models 
described here prove a means to study the diagnostic meaning and value of imaging of vascular calcification, leading to clinical 
applications; however, the present data do not indicate that the advantages in stability and mineral affinity displayed by the new 
complexes translate into practical advantages in imaging compared to conventional 99mTc-bisphosphonate tracers such as 99mTc-1. 
Finally, [188Re]-8 deserves further biological evaluation as a radiopharmaceutical for palliative treatment of bone metastases 
because of its high in vivo stability, selective uptake in bone and joints, and low retention in kidney at 24 h. 
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